HAB Pharma Expands Footprint with New Dehradun Facility to Drive Innovation in Healthcare

HAB Pharmaceutical & Research Ltd., a prominent name in pharmaceutical manufacturing, has announced the acquisition of a 10-acre plot in Dehradun, marking a major step in the company’s ambitious expansion plans. The site, formerly owned by Elder Pharmaceuticals Ltd., represents a strategic move to enhance HAB Pharma’s manufacturing capabilities and meet rising demand in the healthcare sector.

Founded in 1989 by entrepreneurs KK Agrawal and Sanjiv Garg, HAB Pharma has evolved into a powerhouse in the industry, known for its innovation, high-speed production lines, and robust manufacturing capabilities. The company’s portfolio includes trusted products like Nu Turboderm and Multi 9 tablets, making it a preferred partner for major pharmaceutical giants.

The newly acquired Dehradun site will house a state-of-the-art Metered Dose Inhaler (MDI) manufacturing facility, addressing the growing demand for respiratory treatments. Additionally, the company is venturing into biologics, with a focus on treatments for autoimmune disorders — a rapidly expanding segment in advanced healthcare solutions.

HAB Pharma currently operates two world-class facilities — one in Vasai, Mumbai, and another in Dehradun. Its sister concern, Signature Phytochemical, further bolsters its manufacturing strength with three units in Dehradun, including specialized blocks for beta-lactam and cephalosporin products. The recent launch of a cutting-edge beta-lactam dry powder injectable facility further enhances the company’s production capabilities.

HAB’s CFO Ganesh Poojari said, “We are committed to delivering world-class pharmaceutical solutions, and this expansion will enable us to broaden our product portfolio, enhance our R&D capabilities, and better serve the evolving needs of our customers and patients.”

Renowned for its commitment to quality and efficiency, HAB Pharma is a trusted contract manufacturer for leading pharmaceutical companies such as Zydus Lifesciences and Alkem Laboratories. The company’s ability to deliver high-quality products at scale has solidified its position as a key player in the global pharmaceutical supply chain.

HAB Pharma’s dedicated formulation development team continuously works on new product innovations, supported by rigorous bioequivalence studies to ensure optimal efficacy. The company’s investments in formulations with enhanced bioavailability further reinforce its focus on delivering effective healthcare solutions.

With its latest expansion, HAB Pharma is poised to redefine pharmaceutical manufacturing in India and beyond. The company’s commitment to innovation, quality, and patient well-being continues to drive its mission of advancing global healthcare standards.